Cystadrops
What Cystadrops is used for
Cystadrops is indicated for the treatment of corneal cystine crystal deposits in adults and children from 6 months of age with cystinosis.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Cystadrops
- Active substance
- mercaptamine
- Disease area
- Cystinosis
- Medicine group
- Ophthalmologicals
- ATC code
- S01XA21
- Marketing authorisation holder
- Recordati Rare Diseases
- Authorised in the EU since
- 2017
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Cystadrops used for?
Cystadrops is indicated for the treatment of corneal cystine crystal deposits in adults and children from 6 months of age with cystinosis.
What is the active substance in Cystadrops?
Cystadrops contains mercaptamine.
Who makes Cystadrops?
The EU marketing authorisation holder is Recordati Rare Diseases.
Is Cystadrops an orphan medicine?
Yes. Cystadrops is designated an orphan medicine in the EU, for a rare disease (Cystinosis).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU